Built by the scientists who redefined RNA delivery —
and are now redefining cancer therapy.
Our Mission
To pioneer safe, scalable, and powerful immunotherapies that harness the body’s full immune potential against cancer.
Our Vision
Empowering global health utilizing Synthetic Biology with a universal RNA-Lipid Nanoparticle (LNP) platform for cancer immunotherapies.
Our Edge
World-class expertise in Synthetic Biology and Lipid Nanoparticles with a next-gen modular platform mimicking natural viral infections without the risks.
Built from two world-leading labs, ViVac pioneers biotechnology by uniting synthetic biology and lipid nanoparticle science to develop RNA-based immunotherapies that safely eliminate cancer from within.
Our team unites world-class scientists, entrepreneurs, and industry leaders dedicated to one mission:
To reprogram the immune system’s language — and give it the power to outsmart cancer.
Leadership Team
ViVac is led by a world-class team of pioneers in synthetic biology, nanomedicine, and biotech innovation — united by a shared mission to transform how cancer is treated.
CEO
Keren Leshem
A World Economic Forum Technology Pioneer CEO and globally recognized biotech leader, Keren brings over 20 years of experience guiding clinical-stage companies from concept to commercialization.
Featured in Forbes and Entrepreneur, she drives ViVac’s vision to translate cutting-edge science into transformative cancer therapies.
Head of Membrane & Liposome Lab
Prof. Chezy Barenholz
A globally recognized authority in nanomedicine and listed among Stanford’s top 2% of scientists, Prof. Barenholz invented Doxil®, the world’s first FDA-approved liposomal nanodrug. As a member of ViVac’s Board of Directors, he advances next-generation lipid nanoparticle engineering to deliver RNA safely and with unprecedented precision.
Head of Synthetic Biology Lab
Prof. Lior Nissim
A leading authority in synthetic and cancer biology, Prof. Nissim developed the world’s first synthetic gene circuit capable of sensing and responding to tumor signals.
At ViVac, he pioneers RNA blueprint design that programs precise therapeutic activity inside tumors, transforming synthetic biology into a targeted weapon against cancer.
Chief Technology Officer
Dr. Ron Lahav
With over two decades of experience in RNA delivery, oncology, and biotech innovation, Dr. Lahav bridges scientific discovery and real-world application. Having led R&D at multiple startups and at the National Institute for Biotechnology in the Negev, he brings deep expertise in nanoparticle formulation and translational development. He oversees ViVac’s translational programs.
What began as a viral vaccine revolution is now rewriting the future of cancer therapy.
Renowned Life Science Investors
Michael Vaknin
Shareholder
J.P. Morgan | Goldman Sachs
Tuomas Tenkanen
ViVac Board Director
Thermo Fischer | Mobidiag
Dr. Jean De Gunzburg
ViVac Board Director
Inserm | Da Volterra
